Literature DB >> 19048281

Surgical aspects and complications of continuous intraperitoneal insulin infusion with an implantable pump.

Jan Willem Haveman1, Susan J J Logtenberg, Nanne Kleefstra, Klaas H Groenier, Henk J G Bilo, Adri M Blomme.   

Abstract

PURPOSE: Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump is safe and effective in selected subjects with diabetes. Our aim was to assess surgical experience and complications with CIPII.
METHODS: We performed a retrospective longitudinal observational cohort study of patients that started with CIPII from 1990 to 2006. Operation free period and complication rate were compared between patients initiating CIPII before 2000 and from 2000 onwards.
RESULTS: In 63 patients, 166 re-operations were performed during 381 patient-years. Re-operations were pump replacement due to end-of-battery life (47%), laparoscopic catheter-related procedures (29%) and other interventions (24%). Median operation free period increased from 21 to 78 months from 2000 onwards (p = 0.039). Nineteen percent of patients developed complications. No operation-related mortality was reported.
CONCLUSIONS: Increased experience together with technical improvements has led to an increase of the operation free period. The absence of procedure-related mortality and a low complication rate makes CIPII feasible for selected patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048281     DOI: 10.1007/s00423-008-0437-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  17 in total

Review 1.  Treatment of infections associated with surgical implants.

Authors:  Rabih O Darouiche
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

2.  Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study.

Authors:  L Dufaitre-Patouraux; J P Riveline; E Renard; V Melki; P Belicar-Schaepelynck; J L Selam; B Guerci; L Millot; J M Brun; C Fermon; B Catargi; H Gin; N Jeandidier; P J Lejeune; V Lassmann-Vague
Journal:  Diabetes Metab       Date:  2006-11       Impact factor: 6.041

3.  Glycaemic control, health status and treatment satisfaction with continuous intraperitoneal insulin infusion.

Authors:  S J J Logtenberg; E van Ballegooie; H Israêl-Bultman; A van Linde; H J G Bilo
Journal:  Neth J Med       Date:  2007-02       Impact factor: 1.422

4.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

5.  Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group.

Authors:  C D Saudek; W C Duckworth; A Giobbie-Hurder; W G Henderson; R R Henry; D E Kelley; S V Edelman; F J Zieve; R A Adler; J W Anderson; R J Anderson; B P Hamilton; T W Donner; M S Kirkman; N A Morgan
Journal:  JAMA       Date:  1996 Oct 23-30       Impact factor: 56.272

6.  Intraperitoneal delivery of insulin via mechanical pump: surgical implications.

Authors:  R Udelsman; M S Boyne; K E Loman; C D Saudek
Journal:  Langenbecks Arch Surg       Date:  2000-10       Impact factor: 3.445

7.  Implanted programmable insulin pumps: one hundred fifty-three patient years of surgical experience.

Authors:  R Udelsman; H Chen; K Loman; H A Pitt; C D Saudek
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

8.  Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients.

Authors:  J L Selam; D Raccah; N Jean-Didier; J L Lozano; K Waxman; M A Charles
Journal:  Diabetes Care       Date:  1992-01       Impact factor: 19.112

9.  French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society.

Authors:  C Broussolle; N Jeandidier; H Hanaire-Broutin
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

10.  Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.

Authors:  D M Nathan; F L Dunn; J Bruch; C McKitrick; M Larkin; C Haggan; J Lavin-Tompkins; D Norman; D Rogers; D Simon
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

View more
  11 in total

1.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

2.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

Review 3.  Finding the right route for insulin delivery - an overview of implantable pump therapy.

Authors:  Lia Bally; Hood Thabit; Roman Hovorka
Journal:  Expert Opin Drug Deliv       Date:  2016-12-07       Impact factor: 6.648

4.  Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial.

Authors:  Susan J Logtenberg; Nanne Kleefstra; Sebastiaan T Houweling; Klaas H Groenier; Reinold O Gans; Henk J Bilo
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 17.152

5.  Complications of continuous intraperitoneal insulin infusion with an implantable pump.

Authors:  Peter R van Dijk; Susan Jj Logtenberg; Klaas H Groenier; Jan Willem Haveman; Nanno Kleefstra; Henk Jg Bilo
Journal:  World J Diabetes       Date:  2012-08-15

6.  Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up.

Authors:  Peter R van Dijk; Susan J J Logtenberg; Klaas H Groenier; Rijk O B Gans; Nanne Kleefstra; Henk Jg Bilo
Journal:  BMC Endocr Disord       Date:  2014-04-07       Impact factor: 2.763

7.  Implantable batteryless device for on-demand and pulsatile insulin administration.

Authors:  Seung Ho Lee; Young Bin Lee; Byung Hwi Kim; Cheol Lee; Young Min Cho; Se-Na Kim; Chun Gwon Park; Yong-Chan Cho; Young Bin Choy
Journal:  Nat Commun       Date:  2017-04-13       Impact factor: 14.919

8.  Different routes of insulin administration do not influence serum free thiols in type 1 diabetes mellitus.

Authors:  Peter R van Dijk; Femke Waanders; Susan J J Logtenberg; Klaas H Groenier; Titia M Vriesendorp; Nanne Kleefstra; Harry van Goor; Henk J G Bilo
Journal:  Endocrinol Diabetes Metab       Date:  2019-08-08

9.  Glucose sensing in the peritoneal space offers faster kinetics than sensing in the subcutaneous space.

Authors:  Daniel R Burnett; Lauren M Huyett; Howard C Zisser; Francis J Doyle; Brett D Mensh
Journal:  Diabetes       Date:  2014-03-12       Impact factor: 9.461

Review 10.  An Overview of Insulin Pumps and Glucose Sensors for the Generalist.

Authors:  Brooke H McAdams; Ali A Rizvi
Journal:  J Clin Med       Date:  2016-01-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.